Target intelligence / Profile preview

Anxiety response pathway

Molecular classification
Other (not a single molecule, receptor, or protein family; refers to a collection of molecular and cellular pathways)
01

Overview

The term "Anxiety response pathway" does not refer to a single defined molecule, receptor, enzyme, transporter, or other canonical therapeutic target. Instead, it is an umbrella term describing complex networks of molecular cascades and signaling events in the brain that mediate behavioral and physiological responses to stress and contribute to anxiety-like behaviors. These include multiple interacting systems such as neurotransmitter receptors (GABAergic, serotonergic), kinases (e.g., Src kinase), intracellular second messengers (cAMP/PKA), immune/inflammatory mediators[2][3][1], metabolic processes related to oxidative stress[2], and epigenetic modifications affecting gene expression relevant for mood regulation[4]. Recent research has identified several key molecular nodes within these broader pathways that may serve as potential therapeutic targets. For example: Chronic stress can enhance Src kinase activity leading to downstream effects on synaptic proteins like Neuroligin 2 via MyosinVa interaction; pharmacological inhibition of Src reverses some anxiety-like behaviors in animal models by restoring inhibitory synaptic function.[1] Other studies highlight roles for cAMP/protein kinase A signaling in regulating amygdala-driven fear learning and emotional reactivity,[3] immune system involvement through neuroinflammation,[2] metabolic redox balance,[2] and epigenetic mechanisms such as histone acetylation/deacetylation influencing gene transcription relevant for stress adaptation.[4] Because "Anxiety response pathway" is not itself a discrete molecule or protein but rather encompasses many interconnected biological processes across different cell types and brain regions,[1][2][3][4] it cannot be classified under standard categories like receptor/enzyme/transporter/etc., nor does it have canonical abbreviations or aliases used in scientific literature. In summary: This entry is not suitable as a canonical drug target because it lacks specificity—it refers instead to broad biological processes involving many distinct molecules which themselves may be valid therapeutic targets.

Other names
Anxiety pathwayAnxiety signaling pathwayStress response pathway (context-dependent)
02

Biological functions

Signal transductionStress responseRegulation of mood and emotionNeurotransmission modulation
03

Disease associations

Neuropsychiatric disorders (including anxiety disorders)DepressionOther stress-related conditions

Beyond the preview

Go deeper on Anxiety response pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anxiety response pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call